Effects of Manidipine and Nifedipine on Blood Pressure and Renal Function in Patients with Chronic Renal Failure: A Multicenter Randomized Controlled Trial

Figures & data

Table 1. Initial characteristics of subjects

	Manidipine	Nifedipine
No. of patients	50	48
Gender (males/females)	37/22	38/18
Age (years)	50.7 ± 11.9	51.3 ± 10.9
Body weight (kg)a	70.2 ± 10.9	67.0 ± 11.1
Laboratory measurements (Mean ± SD)
SBP (mm/Hg)	162.3 ± 15.4	163.5 ± 15.7
BP (mm/Hg)	97.2 ± 7.5	98.1 ± 9.5
Heart rate (beats/min)	76.5 ± 11.1	75.4 ± 9.1
Creatinine blood levels (mg/dL)	2.3 ± 1.0	2.5 ± 1.1
Creatinine clearance (mL/min)	38.4 ± 19.5	37.6 ± 16.4
Proteinuria (mg/24 h)a	1195.1 ± 1364.5	912.4 ± 981.4
Causes of renal impairmentb
Chronic glomerulonephritis	31.3 (19.0–46.4)	18.0 (9.0–31.9)
Hypertensive nephropathy	25.0 (14.1–39.8)	28.0 (16.6–47.2)
Diabetic nephropathy	10.4 (3.8–23.4)	10.0 (3.7–22.5)
Reflux nephropathy	8.3 (2.7–20.8)	2.0 (0.1–12.0)
Tubulo-interstitial nephropathy	6.3 (1.6–18.2)	6.0 (1.5–17.5)
Polycystic kidney	2.0 (0.1–12.4)	12.0 (4.9–25.0)
Other	16.7 (7.9–30.7)	24.0 (13.5–38.4)

SBP: systolic blood pressure; DBP: diastolic blood pressure.

^aP<0.05; a significant difference between the groups.

^bPercentages and 95% confidence intervals.

Table 2. Effects of treatments with manidipine and nifedipine in reducing blood pressure

	Manidipine			Nifedipine
Blood pressure	Baseline	End of follow-up	Mean change (95% CI)	Baseline	End of follow-up	Mean change (95% CI)
Sitting
DBP (mm/Hg)	99.8 ± 4.7	85.2 ± 9.1	14.5 (11.7−7.4)	102.2 ± 6.2	84.8 ± 6.4	17.4 (15.0−19.8)
SBP (mm/Hg)	166.7 ± 47.5	147.8 ± 15.2	19.0 (13.6−24.4)	169.3 ± 16.2	143.8 ± 9.9	25.5 (20.8−30.2)
Standing
DBP (mm/Hg)	100.2 ± 5.2	86.4 ± 9.1	13.8 (10.9−16.6)	102.3 ± 6.9	85.5 ± 6.4	16.8 (14.2−19.3)
SBP (mm/Hg)	166.3 ± 13.3	146.5 ± 15.8	19.8 (14.5−25.2)	166.2 ± 17.6	142.2 ± 11.4	24.0 (18.9−29.2)

Table 3. Effects of treatments on renal functions.a

	Manidipine		Nifedipine
	Visit 2	Visit 7	Visit 2	Visit 7
Creatinine blood levels (mg/dL)	2.3 ± 1.0	2.1 ± 0.9b	2.5 ± 1.1	2.5 ± 1.4
Creatinine clearance (mL/min)	38.4 ± 19.5	44.8 ± 21.3c	37.6 ± 16.4	38.2 ± 19.3
Proteinuria (mg/24 h)	1195.1 ± 1364.5	890.3 ± 1156.2	912.4 ± 981.4	1234.3 ± 2101.9b
Sodium (mEq/24 h)	122.7 ± 50.9	125.3 ± 47.8	139.0 ± 122.6	133.7 ± 71.0
Potassium (mEq/24 h)	48.1 ± 18.7	50.3 ± 17.7	50.2 ± 45.9	42.8 ± 18.8

^aAnalysis within treatment on the differences compared to basal values (Visit 7/Visit 2); significant changes from baseline values.

^bp<0.05.

^cp<0.001.

Table 4. Mean laboratory measurements for patients at baseline and after treatments

	Manidipine		Nifedipine
	Visit 2	Visit 7	Visit 2	Visit 7
Glucose (mg/dL)	96.6	94.2	92.8	93.6
Sodium (mEq/L)	141.5	141.7	140.8	141.5
Potassium (mEq/L)	4.7	4.7	4.7	4.7
Calcium (mg/dL)	9.3	9.4	9.3	9.6
Phosphorus (mg/dL)	3.8	4.1	3.9	4.0
Total bilirubin (mg/dL)	0.6	0.6	0.6	0.6
Total cholesterol (mg/dL)	216.1	220.7	221.4	229.4
HDL-cholesterol (mg/dL)	54.3	54.2	53.2	52.4
Triglyceride (mg/dL)	149.6	125.3	164.8	169.4
SGOT (U/L)	19.9	18.9	18.6	20.1
SGPT (U/L)	20.7	19.1	19.2	20.1
LDH (U/L)	279.3	248.6	294.7	276.1